Lifesci Capital Issues Optimistic Estimate for VRDN Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Lifesci Capital raised their FY2025 earnings per share estimates for Viridian Therapeutics in a research report issued on Wednesday, November 5th. Lifesci Capital analyst R. Katkhuda now forecasts that the company will post earnings of ($3.15) per share for the year, up from their previous estimate of ($3.96). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Lifesci Capital also issued estimates for Viridian Therapeutics’ Q4 2025 earnings at ($0.94) EPS.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.48. Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $16.21 million. The company’s revenue for the quarter was up 81993.0% compared to the same quarter last year.

Other equities analysts also recently issued research reports about the stock. BTIG Research reaffirmed a “buy” rating and set a $61.00 price target on shares of Viridian Therapeutics in a report on Tuesday, November 4th. Oppenheimer lifted their target price on shares of Viridian Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Tuesday, October 21st. Needham & Company LLC cut their price target on Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada upped their price objective on Viridian Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $39.78.

Viridian Therapeutics Trading Up 0.8%

Shares of NASDAQ:VRDN opened at $27.65 on Monday. The stock has a 50 day moving average of $21.49 and a 200 day moving average of $17.67. The company has a market cap of $2.64 billion, a PE ratio of -7.22 and a beta of 0.72. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $28.60. The company has a current ratio of 11.01, a quick ratio of 11.01 and a debt-to-equity ratio of 0.04.

Insiders Place Their Bets

In other news, Director Fairmount Funds Management Llc acquired 454,545 shares of Viridian Therapeutics stock in a transaction on Thursday, October 23rd. The shares were acquired at an average price of $22.00 per share, with a total value of $9,999,990.00. Following the purchase, the director directly owned 3,914,458 shares in the company, valued at $86,118,076. The trade was a 13.14% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.58% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Commodore Capital LP raised its stake in Viridian Therapeutics by 35.4% during the second quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after purchasing an additional 1,275,000 shares in the last quarter. Rice Hall James & Associates LLC grew its stake in shares of Viridian Therapeutics by 65.2% in the 3rd quarter. Rice Hall James & Associates LLC now owns 851,663 shares of the company’s stock worth $18,379,000 after buying an additional 336,040 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Viridian Therapeutics by 33.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after buying an additional 310,998 shares during the last quarter. HighVista Strategies LLC raised its position in shares of Viridian Therapeutics by 168.4% during the 2nd quarter. HighVista Strategies LLC now owns 484,559 shares of the company’s stock valued at $6,774,000 after buying an additional 304,008 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP lifted its holdings in shares of Viridian Therapeutics by 15.1% in the 1st quarter. Paradigm Biocapital Advisors LP now owns 2,095,079 shares of the company’s stock valued at $28,242,000 after acquiring an additional 275,000 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.